Literature summary for 3.1.3.11 extracted from

Muindi, J.R.; Peng, Y.; Wilson, J.W.; Johnson, C.S.; Branch, R.A.; Trump, D.L.
Monocyte fructose 1,6-bisphosphatase and cytidine deaminase enzyme activities: potential pharmacodynamic measures of calcitriol effects in cancer patients (2006), Cancer Chemother. Pharmacol., 59, 97-104.

Search for more literature for 3.1.3.11

Application

Application	Comment	Organism
medicine	all calcitriol doses increase cancer patient peripheral blood monocyte enzyme activity to normal levels and decrease cytidine deaminase activity to undetectable levels within 48 h, with no significant change in 24-hydrolase activity. Enzyme activity changes are not associated with hypercalcemia	Homo sapiens
medicine	calcitriol treatment-induced increase in FBPase activity in patient peripheral blood monocytes of cancer patients are potential early and sensitive non-hypercalcemia pharmacodynamic measures of calcitriol effects	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-
Homo sapiens	-	cancer patients enrolled in phase I clinical trial of calcitriol and carboplatin	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
monocyte	peripheral blood monocyte	Homo sapiens	-
monocyte	peripheral blood monocyte. baseline activity of fructose 1,6-bisphosphatase in cancer patients is 1.0 nmol/min/mg protein, and 4.4 nmol/min/mg for healthy volunteers	Homo sapiens	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)